OncoSil™ Indications
OncoSil™ is indicated in locally advanced unresectable pancreatic cancer.
OncoSil™ implantation procedure
OncoSil™ implantation is performed using endoscopy.
OncoSil™ clinical development
OncoSil™ has been studied in two clinical trials.
OncoSil™ indications
Pancreatic cancer
Intended use3
OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance.
Indication3
OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer,‘Locally advanced’ cancer remains confined to the pancreas and nearby structures. Locally advanced cancer may be unresectable (this means it is unable to be removed completely with surgery) if the tumour is too large or too close to nearby blood vessels to be removed safely.4-6 in combination with gemcitabine-based chemotherapy.
The OncoSil™ System is supplied sterile and is intended for single-patient, single-use.
OncoSil™ implantation procedure
The OncoSil™ implantation procedure is performed in a licensed treatment facility by an endoscopist.
OncoSil™ implantation is an outpatient procedure, although some patients may be required to stay overnight depending on the treating clinician’s assessment.
Overview of OncoSil™ implantation
A dose of the OncoSil™ Microparticle suspension, containing a pre-determined amount of radiation, is injected directly into the tumour
OncoSil™ clinical development
Unresectable locally advanced pancreatic cancer
OncoSil™ has been studied in combination with standard-of-care chemotherapy for the treatment of patients with unresectable locally advanced pancreatic cancer in two active clinical trials. Both trials are now closed to recruitment.
A single-arm open-label pilot study of OncoSil™ in patients treated with FOLFIRINOX or gemcitabine + nab-paclitaxel chemotherapy.
Conducted in Australia, the United Kingdom and Belgium.
For more details of the PanCO study visit ClinicalTrials.gov
A single-arm open-label pilot study of OncoSil™ in patients treated with gemcitabine ± nab-paclitaxel chemotherapy.
Conducted in the United States of America.
For more details of the OncoPaC-1 study visit ClinicalTrials.gov
REFERENCES 1. Skowronek J. J Contemp Brachytherapy 2017; 9: 581–589. 2. Australian Nuclear Science and Technology Organisation (ANSTO). www.ansto.gov.au/education/nuclear-facts/what-are-radioisotopes (accessed July 2020). 3. OncoSil™ System instructions for use EMEA. 4. Balaban EP et al. J Clin Oncol. 2016; 34: 2654–2668. 5. Ducreux M et al. Ann Oncol. 2015; 26 Suppl 5: v56–68. 6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma. Version 1.2020.
WB02-I-0720